Cost-effectiveness comparison of three different natural surfactant preparations in the treatment of preterm infants with respiratory distress syndrome

Mustafa Şenol Akın; Ufuk Çakır

Makale detayları

Cost-effectiveness comparison of three different natural surfactant preparations in the treatment of preterm infants with respiratory distress syndrome

Yazarlar:

Mustafa Şenol Akın | Ufuk Çakır

Yayıncı:

Cukurova University

Ana Başlıklar:

Yenidoğan

Dergi:

Cukurova Medical Journal Vol.50 Issue 1, pp.73-82

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343857

pISSN:

2602-3032

Anahtar kelimeler:

Özet:

 Purpose: This study aimed to assess the cost-effectiveness of three natural surfactants by analyzing their initial impact on respiratory and blood gas variables and their associated costs. Materials and Methods: This study included preterm infants with respiratory distress syndrome RDS born before the 32nd gestational week who received exogenous surfactant replacement therapy in a tertiary neonatal intensive care unit NICU between September 2019 and December 2022. Data from 985 patients were retrospectively obtained from medical records. Results: Among the enrolled patients, 575 received Poractant Alfa 58, 343 received Beractant 35, and 67 received Calfactant 7. No significant differences were observed between the surfactant groups in terms of short-term pulmonary improvement, complications, clinical outcomes, or costs. However, in subgroup analysis based on birth weights, Calfactant 331.57162.54  was found to be significantly more cost-effective than Beractant 507.50175.50  and Poractant Alfa 472.4493.73  for infants weighing 750-999 grams. Furthermore, for infants weighing 1000-1499 grams, both Beractant 497.47168.55  and Calfactant 531.54293.20  were significantly less costly than Poractant Alfa 669.36265.23 . Conclusions: This study demonstrated comparable short-term respiratory improvements, complications, and clinical outcomes among surfactant groups, emphasizing the potential influence of cost on surfactant choice. A novel model for selecting surfactant preparations based on birth weights was proposed, suggesting the use of Calfactant for infants weighing 750-999 grams and considering the use of Poractant Alfa for infants weighing 1000-1499 grams.

 Purpose: This study aimed to assess the cost-effectiveness of three natural surfactants by analyzing their initial impact on respiratory and blood gas variables and their associated costs. Materials and Methods: This study included preterm infants with respiratory distress syndrome RDS born before the 32nd gestational week who received exogenous surfactant replacement therapy in a tertiary neonatal intensive care unit NICU between September 2019 and December 2022. Data from 985 patients were retrospectively obtained from medical records. Results: Among the enrolled patients, 575 received Poractant Alfa 58, 343 received Beractant 35, and 67 received Calfactant 7. No significant differences were observed between the surfactant groups in terms of short-term pulmonary improvement, complications, clinical outcomes, or costs. However, in subgroup analysis based on birth weights, Calfactant 331.57162.54  was found to be significantly more cost-effective than Beractant 507.50175.50  and Poractant Alfa 472.4493.73  for infants weighing 750-999 grams. Furthermore, for infants weighing 1000-1499 grams, both Beractant 497.47168.55  and Calfactant 531.54293.20  were significantly less costly than Poractant Alfa 669.36265.23 . Conclusions: This study demonstrated comparable short-term respiratory improvements, complications, and clinical outcomes among surfactant groups, emphasizing the potential influence of cost on surfactant choice. A novel model for selecting surfactant preparations based on birth weights was proposed, suggesting the use of Calfactant for infants weighing 750-999 grams and considering the use of Poractant Alfa for infants weighing 1000-1499 grams.

 Purpose: This study aimed to assess the cost-effectiveness of three natural surfactants by analyzing their initial impact on respiratory and blood gas variables and their associated costs. Materials and Methods: This study included preterm infants with respiratory distress syndrome RDS born before the 32nd gestational week who received exogenous surfactant replacement therapy in a tertiary neonatal intensive care unit NICU between September 2019 and December 2022. Data from 985 patients were retrospectively obtained from medical records. Results: Among the enrolled patients, 575 received Poractant Alfa 58, 343 received Beractant 35, and 67 received Calfactant 7. No significant differences were observed between the surfactant groups in terms of short-term pulmonary improvement, complications, clinical outcomes, or costs. However, in subgroup analysis based on birth weights, Calfactant 331.57162.54  was found to be significantly more cost-effective than Beractant 507.50175.50  and Poractant Alfa 472.4493.73  for infants weighing 750-999 grams. Furthermore, for infants weighing 1000-1499 grams, both Beractant 497.47168.55  and Calfactant 531.54293.20  were significantly less costly than Poractant Alfa 669.36265.23 . Conclusions: This study demonstrated comparable short-term respiratory improvements, complications, and clinical outcomes among surfactant groups, emphasizing the potential influence of cost on surfactant choice. A novel model for selecting surfactant preparations based on birth weights was proposed, suggesting the use of Calfactant for infants weighing 750-999 grams and considering the use of Poractant Alfa for infants weighing 1000-1499 grams.

 Amaç: Bu çalışma, üç doğal surfaktanın maliyet-etkinliğini, respiratuvar ve kan gazı değişkenleri üzerindeki başlangıç etkileri ve ilişkili maliyetleri analiz ederek değerlendirmeyi amaçlamıştır. Gereç ve Yöntem: Bu çalışmaya, Eylül 2019 ile Aralık 2022 tarihleri arasında üçüncü basamak yenidoğan yoğun bakım ünitesinde YYBÜ eksojen surfaktan replasman tedavisi almış, 32. gebelik haftasından önce doğmuş respiratuvar distres sendromu RDS tanılı preterm bebekler dahil edilmiştir. 985 hastaya ait veriler tıbbi kayıtlardan retrospektif olarak elde edilmiştir. Bulgular: Çalışmaya dahil edilen hastaların 58i n575 Poraktant Alfa, 35i n343 Beraktant ve 7si n67 Kalfaktant almıştır. Surfaktan grupları arasında kısa dönem pulmoner iyileşme, komplikasyonlar, klinik sonuçlar veya maliyetler açısından anlamlı bir fark gözlenmemiştir. Ancak, doğum ağırlıklarına göre yapılan alt grup analizinde, 750-999 gram ağırlığındaki bebeklerde Kalfaktantın 331,57162,54 , Beraktant 507,50175,50  ve Poraktant Alfaya 472,4493,73  göre anlamlı şekilde daha maliyet-etkin olduğu bulunmuştur. Ayrıca, 1000-1499 gram ağırlığındaki bebeklerde Beraktant 497,47168,55  ve Kalfaktantın 531,54293,20  Poraktant Alfaya 669,36265,23  göre anlamlı şekilde daha düşük maliyetli olduğu görülmüştür. Sonuç: Bu çalışma, surfaktan grupları arasında benzer kısa dönem respiratuvar iyileşme, komplikasyonlar ve klinik sonuçlar gözlemlendiğini, ancak maliyetin surfaktan seçiminde potansiyel olarak önemli bir rol oynayabileceğini göstermiştir. Doğum ağırlıklarına dayalı surfaktan seçimi için yeni bir model önerilmiştir. Buna göre, 750-999 gram ağırlığındaki bebekler için Kalfaktantın, 1000-1499 gram ağırlığındaki bebekler için ise Poraktant Alfanın tercih edilmesi önerilmektedir.

Makale detayları

Cost-effectiveness comparison of three different natural surfactant preparations in the treatment of preterm infants with respiratory distress syndrome

Yazarlar:

Mustafa Şenol Akın | Ufuk Çakır

Yayıncı:

Cukurova University

Ana Başlıklar:

Yenidoğan

Dergi:

Cukurova Medical Journal Vol.50 Issue 1, pp.73-82

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343857

pISSN:

2602-3032

Premature infants

Neonatal Respiratory Distress Syndrome

Pulmonary Surfactants

Cost EffectivenessPrematüre bebekler

Neonatal Respiratuvar Distres Sendromu

Pulmoner Surfaktanlar

Maliyet Etkinliği

Sayı

Makale detayları

Yazarlar: Mustafa Şenol Akın | Ufuk Çakır

Yayıncı: Cukurova University

Ana Başlıklar: Yenidoğan

Dergi: Cukurova Medical Journal Vol.50 Issue 1, pp.73-82

Belge Tipi: Makale

Yayın Tarihi: 3/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001343857

pISSN: 2602-3032

Sayı

Yazarlar:

Mustafa Şenol Akın | Ufuk Çakır

Yayıncı:

Cukurova University

Ana Başlıklar:

Yenidoğan

Dergi:

Cukurova Medical Journal Vol.50 Issue 1, pp.73-82

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343857

pISSN:

2602-3032